PMID- 27188866
OWN - NLM
STAT- MEDLINE
DCOM- 20170123
LR  - 20221207
IS  - 1165-158X (Electronic)
IS  - 0145-5680 (Linking)
VI  - 62
IP  - 5
DP  - 2016 Apr 30
TI  - Are there possible associations between MnSOD and GPx1 gene variants for 
      laryngeal cancer risk or disease progression?
PG  - 25-30
AB  - Laryngeal squamous cell carcinoma (LSCC) is a multifaceted and genomically 
      complex disease and cellular and preclinical studies have demystified wide 
      ranging molecular mechanisms which underpin its development and progression and 
      resistance against wide ranging molecular therapeutics. Oxidative stress is a 
      widely studied molecular mechanism and reportedly involved in carcinogenesis. 
      Increasingly it is being realized that accumulation of Reactive Oxygen Species 
      (ROS) activates defensive mechanism to counteract oxidative stress induced 
      damage. Manganese superoxide dismutase (MnSOD) and glutathione peroxidase (GPx) 
      are important members of defensive machinery. We investigated whether the 
      polymorphisms of MnSOD (Ala-9Val, rs4880) and GPx1 (Pro198Leu, rs1050450) are 
      associated with LSCC and also evaluated possible interactions between these 
      polymorphisms and various lifestyle factors or pathological features of patients. 
      For this purpose, 67 LSCC patients and 73 healty controls were enrolled. 
      Molecular assessment of MnSOD and GPx1 variants were determined with polymerase 
      chain reaction-restriction fragment length polymorphism techniques. We found that 
      the frequency of both heterozygous PL genotype and P allele was considerably 
      higher in patients with advanced tumor stage (T3/T4) than in those with early 
      tumor stage (T1/T2) (OR= 5.106; 95% CI=1.372-19.004; p<0.001, OR=5.787; 95% CI 
      =1.564-21.414; p<0.001 respectively). Although the frequency of ValVal/LL combine 
      genotype was significantly decreased (OR=0.204, 95% CI=0.055-0.760; p=0.021), the 
      frequency of ValAla/PL combine genotypes was higher in patients with stage T3/T4 
      than in those patients with stage T1/T2 (p=0.027). Consequently, we have 
      concluded that variants of GPx1 and MnSOD should not be considered as a risk 
      factor of LSCC, only may be accepted as a prognostic markers. Use of new 
      technologies such as metabolomics and deep DNA sequencing will prove to be 
      helpful in developing a deeper knowledge related to how cancer cell metabolism 
      adapts and provides a buffer against increased oxidative stress.
FAU - Coskun, C
AU  - Coskun C
AD  - Haseki Training and Research Hospital Department of Biochemistry Istanbul Turkey.
FAU - Verim, A
AU  - Verim A
AD  - Haydarpasa Training and Research Hospital Otorhinolaryngology Clinic Istanbul 
      Turkey.
FAU - Farooqi, A A
AU  - Farooqi AA
AD  - Rashid Latif Medical College Laboratory for Translational Oncology and 
      Personalized Medicine Lahore Pakistan.
FAU - Turan, S
AU  - Turan S
AD  - Istanbul University Department of Molecular Medicine, Institute of Experimental 
      Medicine Istanbul Turkey.
FAU - Mezani, B
AU  - Mezani B
AD  - Istanbul University Department of Molecular Medicine, Institute of Experimental 
      Medicine Istanbul Turkey.
FAU - Kucukhuseyin, O
AU  - Kucukhuseyin O
AD  - Istanbul University Department of Molecular Medicine, Institute of Experimental 
      Medicine Istanbul Turkey.
FAU - Tolgahan Hakan, M
AU  - Tolgahan Hakan M
AD  - Istanbul University Department of Molecular Medicine, Institute of Experimental 
      Medicine Istanbul Turkey.
FAU - Ergen, A
AU  - Ergen A
AD  - Istanbul University Department of Molecular Medicine, Institute of Experimental 
      Medicine Istanbul Turkey.
FAU - Yaylim, I
AU  - Yaylim I
AD  - Istanbul University Department of Molecular Medicine, Institute of Experimental 
      Medicine Istanbul Turkey ilhanyaylim@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20160430
PL  - France
TA  - Cell Mol Biol (Noisy-le-grand)
JT  - Cellular and molecular biology (Noisy-le-Grand, France)
JID - 9216789
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - EC 1.15.1.1 (superoxide dismutase 2)
RN  - EC 1.11.1.9 (Glutathione Peroxidase GPX1)
RN  - EC 1.11.1.9 (GPX1 protein, human)
SB  - IM
MH  - Aged
MH  - *Disease Progression
MH  - Electrophoresis, Agar Gel
MH  - Gene Frequency/genetics
MH  - *Genetic Association Studies
MH  - *Genetic Predisposition to Disease
MH  - Glutathione Peroxidase/*genetics
MH  - Humans
MH  - Laryngeal Neoplasms/*enzymology/*genetics
MH  - Middle Aged
MH  - Polymorphism, Restriction Fragment Length
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Risk Factors
MH  - Superoxide Dismutase/*genetics
MH  - Glutathione Peroxidase GPX1
EDAT- 2016/05/18 06:00
MHDA- 2017/01/24 06:00
CRDT- 2016/05/19 06:00
PHST- 2016/03/23 00:00 [received]
PHST- 2016/04/12 00:00 [accepted]
PHST- 2016/05/19 06:00 [entrez]
PHST- 2016/05/18 06:00 [pubmed]
PHST- 2017/01/24 06:00 [medline]
PST - epublish
SO  - Cell Mol Biol (Noisy-le-grand). 2016 Apr 30;62(5):25-30.